Unicycive Therapeutics (UNCY) Total Liabilities (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Total Liabilities came in at $26.7 million in Q1 2026, up 60.12% YoY from $16.7 million in Q1 2025, and up 41.0% on a QoQ basis from $18.9 million in Q4 2025.
Unicycive Therapeutics (UNCY) Total Liabilities (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Total Liabilities data on file, last reported at $26.7 million in Q1 2026.
- Quarterly Total Liabilities rose 60.12% year-over-year to $26.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.7 million (up 60.12% YoY) and the FY2025 annual result came in at $18.9 million, down 21.86% from the prior year.
- Total Liabilities rose to $26.7 million in Q1 2026, from $18.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $30.7 million in Q1 2024 to a low of $2.5 million in Q1 2022.
- A 5-year average of $14.6 million and a median of $16.0 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 607.13% — and 2025, when it sank 45.6%.
- Tracing UNCY's Total Liabilities over 5 years: stood at $3.3 million in 2022, then soared by 448.11% to $18.0 million in 2023, then soared by 34.65% to $24.2 million in 2024, then declined by 21.86% to $18.9 million in 2025, then surged by 41.0% to $26.7 million in 2026.
- The last three Total Liabilities figures came in at $26.7 million (Q1 2026), $18.9 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 18.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.76 Mn |
| Mar 31, 2026 | 26.70 Mn |
| Dec 31, 2025 | 18.94 Mn |
| Sep 30, 2025 | 13.13 Mn |
| Jun 30, 2025 | 13.57 Mn |
| Mar 31, 2025 | 16.68 Mn |
| Dec 31, 2024 | 24.24 Mn |
| Sep 30, 2024 | 10.72 Mn |
| Jun 30, 2024 | 13.36 Mn |
| Mar 31, 2024 | 30.65 Mn |
| Dec 31, 2023 | 18.00 Mn |
| Sep 30, 2023 | 16.01 Mn |
| Jun 30, 2023 | 16.05 Mn |
| Mar 31, 2023 | 16.69 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 5.55 Mn |
| Jun 30, 2022 | 2.91 Mn |
| Mar 31, 2022 | 2.52 Mn |
| Dec 31, 2021 | 2.26 Mn |
| Sep 30, 2021 | 785,000.00 |